Score: 20/100 (Critical) • Analyzed Jun 2, 2026
This report is based on publicly available sources and is provided for informational purposes only. Estimates and conclusions are algorithmic estimates, not verified facts. See the full disclaimer below.
This report is generated automatically by artificial intelligence based on publicly available information at the time of analysis. It is provided for informational purposes only and does not constitute legal advice, professional consultation, or a definitive assessment of any entity's reputation, character, or business practices.
The scores, findings, and opinions expressed in this report reflect an algorithmic interpretation of publicly indexed web sources and may not be accurate, complete, or up to date. Information on the internet changes frequently, and this report represents a snapshot that may become outdated immediately after generation. We make no warranties regarding the accuracy, reliability, or completeness of any information contained herein.
This report is not intended to defame, disparage, or harm any individual, business, or organization. If you believe any information in this report is inaccurate or unfairly represents you or your organization, please contact us and we will review and correct it promptly.
By viewing this report, you agree that ReputationCalc, its operators, and affiliates shall not be held liable for any decisions made, actions taken, or damages incurred based on the information presented. This report should not be used as the sole basis for any business, employment, investment, or legal decision.
For more information, see our Privacy Policy, Terms of Use, and Data Processing Agreement.
Unlock the Full Power of ReputationCalc
Create a free account to get much more out of every reputation report:
This is an online reputation report for Theranos Inc.. Based on our AI-powered reputation analysis of 224 web sources, Theranos Inc. received an overall reputation score of 20/100 (Critical).
Theranos Inc., once a promising health technology startup, is now defunct following a series of high-profile legal and regulatory issues. The company was dissolved in 2018 after its fraudulent practices were exposed, leading to multiple lawsuits and the conviction of its founder, Elizabeth Holmes.
Theranos Inc. was an American health technology company that claimed to revolutionize blood testing.
224 sources analyzed
Search results are dominated by negative press and legal issues related to fraud.
Theranos has a poor review presence, with low ratings and negative employee feedback.
The company faced extensive negative press due to fraud and regulatory violations.
The brand's reputation is severely damaged, with no positive social trust signals.
The entity is defunct, but its legacy issues continue to impact former associates.
The Total Reputation Score (0–100) is a weighted average of five categories, each scored independently based on AI analysis of publicly available web sources:
Score scale: 80–100 = Excellent, 65–79 = Good, 45–64 = Fair, 25–44 = Poor, 0–24 = Critical. Higher is better — a score of 100 means no negative signals detected.
Scores are algorithmic estimates based on available public data and should not be interpreted as definitive factual measurements of an entity's reputation or business quality.
Matches are based on entity name and may include false positives due to name coincidence, alternate spellings, or similarly named entities. Always verify findings against the original source before drawing conclusions.
Clear means no negative records were found in that database — a positive signal for the entity's reputation.
Issues are identified by AI analysis of publicly available sources. Some findings may reflect outdated information, resolved matters, or misattributed content. We recommend independent verification before acting on any issue listed below.
Elizabeth Holmes was convicted on four counts of fraud and sentenced to 11 years in prison for defrauding investors.
The SEC charged Theranos and its executives with fraud for misleading investors about its technology and business performance.
CMS revoked Theranos's CLIA license and imposed a two-year ban on its executives from operating labs.
Walgreens sued Theranos for breach of contract, seeking $140 million in damages due to fraudulent practices.
Theranos invalidated two years of blood test results due to quality control issues.
Theranos faced a class-action lawsuit alleging consumer fraud over the accuracy of its blood-testing technology.
Investors, including high-profile figures, suffered significant financial losses due to Theranos's fraudulent practices.
The FDA issued a warning about Theranos's use of unapproved devices, questioning its quality control.
A former employee's whistleblower report exposed significant internal issues at Theranos.
Theranos dissolved in 2018 after failing to secure additional funding and facing mounting legal challenges.
Theranos's reputation is significantly worse than typical companies in the health technology industry due to its high-profile fraud case.
This indicates no ongoing international legal or financial concealment issues.
Extensive media coverage ensures public awareness and serves as a deterrent for similar future misconduct.
Regulatory responses to Theranos's actions have strengthened oversight in the healthcare sector.
If ignored: Continued litigation and financial penalties could impact the personal and professional lives of those involved.
Escalation: 6+ months
| # | Lesson | Significance |
|---|---|---|
| 1 | The $140M Walgreens lawsuit demonstrated that retail partners bear financial exposure when partnering with unvalidated diagnostic technology — major pharmacy chains now require independent third-party validation before in-store lab partnerships. | Increased due diligence and validation processes in partnerships. |
| 2 | Holmes's 2022 conviction on 4 counts of wire fraud established that startup CEOs face personal criminal liability for overstating technology capabilities to investors — a precedent now cited in biotech investor due diligence. | Stricter accountability for executive claims in startups. |
| 3 | CMS's 2016 revocation of Theranos's CLIA certificate led to stricter FDA oversight of laboratory-developed tests (LDTs), culminating in the 2024 LDT final rule — diagnostics companies must now factor in this regulatory tightening. | Enhanced regulatory compliance in diagnostics. |
| 4 | Theranos's dissolution in 2018 serves as a lesson in the importance of securing sustainable funding and maintaining financial transparency. | Improved financial practices in startups. |
| 5 | The SEC's fraud charges against Theranos and its executives underscore the necessity for transparent investor communications. | Better investor relations and transparency. |
| 6 | The whistleblower revelations at Theranos highlight the importance of fostering a culture that supports ethical reporting. | Strengthened whistleblower protections and corporate ethics. |
Additional challenges identified through deep analysis — includes both source-reported findings not covered above and signal-based risks derived from available data.
Multiple lawsuits and regulatory actions against Theranos and its executives.
Risk: Continued legal battles could result in further financial and reputational damage.
Theranos faced financial difficulties leading to its dissolution.
Risk: Financial instability can lead to the collapse of business operations.
Regulatory scrutiny from CMS, FDA, and SEC due to non-compliance.
Risk: Non-compliance with regulations can lead to severe penalties and operational bans.
Theranos's failure to achieve market share due to technological shortcomings.
Risk: Inability to compete effectively can result in market exit.
Entity profile: Theranos Inc. was an American health technology company founded in 2003 by Elizabeth Holmes. It claimed to have developed a revolutionary blood-testing technology but was later exposed for fraudulent practices. The company dissolved in 2018 after facing numerous legal challenges and regulatory scrutiny. Theranos raised over $700 million from investors but failed to generate significant revenue due to the failure of its technology. Its main competitors were traditional diagnostic companies like Quest Diagnostics and LabCorp. The company's trajectory highlights the critical importance of transparency and scientific validation in the health technology sector.
Share this page:
Report generated on June 2, 2026 5:00 AM
Powered by AI analysis • 224 web sources scanned
Generated by ReputationCalc
This report is generated automatically by artificial intelligence based on publicly available information at the time of analysis. It is provided for informational purposes only and does not constitute legal advice, professional consultation, or a definitive assessment of any entity's reputation, character, or business practices.
The scores, findings, and opinions expressed in this report reflect an algorithmic interpretation of publicly indexed web sources and may not be accurate, complete, or up to date. Information on the internet changes frequently, and this report represents a snapshot that may become outdated immediately after generation. We make no warranties regarding the accuracy, reliability, or completeness of any information contained herein.
This report is not intended to defame, disparage, or harm any individual, business, or organization. If you believe any information in this report is inaccurate or unfairly represents you or your organization, please contact us and we will review and correct it promptly.
By viewing this report, you agree that ReputationCalc, its operators, and affiliates shall not be held liable for any decisions made, actions taken, or damages incurred based on the information presented. This report should not be used as the sole basis for any business, employment, investment, or legal decision.
For more information, see our Privacy Policy, Terms of Use, and Data Processing Agreement.
Unlock the Full Power of ReputationCalc
Create a free account to get much more out of every reputation report:
Get a free AI-powered reputation analysis for your brand. No sign-up required. Results in under 3 minutes.
Free plan available · No credit card · No commitment
Our support team is here to assist you with any questions
Registered users can contact support directly through the messaging system.